期刊文献+

米拉贝隆的合成工艺改进 被引量:2

Improvement of synthesis process of mirabegron
下载PDF
导出
摘要 米拉贝隆是一种β-3肾上腺素受体的激动剂,用于治疗膀胱过度活动症。本研究在文献方法的基础上,对米拉贝隆的合成工艺进行了改进。以盐酸对硝基苯乙胺、(R)-扁桃酸和2-氨基噻唑-4-乙酸为起始原料,经过酰胺缩合、羰基还原、硝基还原及酰胺缩合4步反应以及一步精制,得到高纯度的目标产物,总收率39%。将第3步硝基还原的氢源,由氢气改为了甲酸铵,增加了工业化可行性;并且对米拉贝隆的精制进行了研究,提高了米拉贝隆的纯度。改进后的工艺操作简化,反应条件温和,为米拉贝隆的制备和精制提供了一种新的方法。 Mirabegron is an agonist of humanβ-3 adrenergic receptor used to treat symptoms of overactive bladder.In this study,the synthesis process of mirabegron was improved based on literatures.Using p-nitrophenethylamine hydrochloride,(R)-mandelicacid and 2-aminothiazole-4-acetic acid as starting materials,the target product with high purity was obtained through four steps of amide condensation,carbonyl reduction,nitro reduction and amide condensation,and one-step purification,with a total yield of 39%.In this study,the hydrogen source of nitro reduction in step 3 was changed from hydrogen to ammonium formate,which increased the feasibility of industrialization,and mirabegron was refined to improve the purity of the product.The improved process has the advantages of simplified operation and mild reaction conditions,which provides a new method for the preparation and purification of mirabegron.
作者 韩成群 邹巧根 孙茜 夏云燕 HAN Chengqun;ZOU Qiaogen;SUN Qian;XIA Yunyan(School of Pharmaceutical Sciences,Nanjing Tech University,Nanjing 211800,China)
出处 《中国药科大学学报》 CAS CSCD 北大核心 2020年第4期449-453,共5页 Journal of China Pharmaceutical University
关键词 米拉贝隆 膀胱过度活动症 硝基还原 工艺改进 合成 mirabegron overactive bladder nitro reduction process improvement synthesis
  • 相关文献

参考文献5

二级参考文献102

  • 1Ellsworth P.Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies[l].Postgrad Med, 2012, 124(3):16-27. 被引量:1
  • 2Emorine W, Marullo S, Briend-sutren MM, et al. Molecular characterization of the human beta 3- adrenergic receptor [J]. Science, 1989,245(4922): 1118-1121. 被引量:1
  • 3Michel MC.~-adrenergic receptor subtypes in the urinary tract[J]. Handb Exp Pharmacol, 2011, (202):307-318. 被引量:1
  • 4Otsuka A, Shinbo H, Matsumoto R, et al. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium [J]. Naunyn Schmiedebergs Arch Pharmacol, 2008, 377(4-6): 473- 481. 被引量:1
  • 5lgawa Y, Michel MC. Pharmacological profile of beta3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome[J]. Naunyn Schmiedebergs Arch Pharmacol, 2013, 386(3): 177-183. 被引量:1
  • 6Kanie S, Otsuka A, Yoshikawa S, et al. Pharmacological effect of TRK-380, a novel selective human beta3-adrenoceptor agonist, on mammalian detrusor strips [J]. Urology, 2012, 79(3):741-747. 被引量:1
  • 7Aizawa N,Homma Y, lgawa Y. Effects of mirabegron, a novel beta3- adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin [J]. Eur Urol, 2012, 62(6): 1165-1173. 被引量:1
  • 8Petkov GV. Role of potassium ion channels in detrusor smooth muscle function and dysfunction [J]. Nat Rev Urol, 2012,9(1): 30-40. 被引量:1
  • 9Michel MC, Ochodnicky P, Homma Y, et al. beta-adrenoceptor agonist effects in experimental models of bladder dysfunction [J]. Pharmacol Ther, 2011,131(1): 40-49. 被引量:1
  • 10Michel MC, Ochodnicky P, Summers R 1. Tissue functions mediated by beta(3)- adrenoceptors- findings and challenges [J]. Naunyn Schmiedebergs Arch Pharmacol, 2010, 382(2): 103-108. 被引量:1

共引文献23

同被引文献6

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部